I believe the valuation has nothing to do with the share price.
SAGA is not buying ENZC shares, the are purchasing two subsidiaries and whatever licenses, technology, intellectual property, products and patents that they hold.
The valuation is based on what is held by Biogenysis, Inc. ("BGEN") and Virogentics Inc. ("VIRO").
Based on today's press release the subsidiaries have a combined value of $450 million dollars.